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Following publication of the original article \[[@CR1]\], the authors identified some errors in Figs. [4](#Fig1){ref-type="fig"}, [5](#Fig2){ref-type="fig"} and [6](#Fig3){ref-type="fig"}; specifically panels Fig. [4](#Fig1){ref-type="fig"}d, Fig. [5](#Fig2){ref-type="fig"}e, and Fig. [6](#Fig3){ref-type="fig"}h. The corrections do not change the results and conclusions of this paper.

The correct figures are given below.

Fig. 4VDAC3 acts as a tumor suppressor. Huh7 and HepG2 cells were transfected with pshR-VDAC3 or controls. HepG2.2.15 cells were transfected with pVDAC3 or controls. Twenty-four hours after transfection, cells were seeded into cell culture inserts. **a** MTT assays were performed to evaluate cell viability. **b** Colony formation assays were used to estimate cell proliferation. **c** Migration/invasion assays and **f** Western blot analyses were used to evaluate EMT. **d** VM and **g** molecular markers of VM were examined to assess tumor angiogenesis. **e** FACS assays were used to examine changes in cell cycle distribution. (\*: *P* \< 0.05)

Fig. 5VDAC3 is a functional target of miR-3928v. HepG2 cells were co-transfected with pCD3/Flag or pVDAC3 and pri-miR-3928v. RT-qPCR and Western blot analyses (**a**) and MTT (**b**), colony formation (**c**), migration (**d**), invasion (**e**) and tube formation assays (**f**) were performed to analyze whether VDAC3 could functionally rescue the miR-3928v-induced phenotype. (\*: *P* \< 0.05, \*\*: *P* \< 0.01, \*\*\*: *P* \< 0.001)

Fig. 6HBx up-regulates miR-3928v expression via EGR1. **a** Schematic diagram of the location of miR-3928v in the human genome; the relative positions of the miR-3928v promoter constructs are shown (left). Luciferase reporter assays were used to examine miR-3928v promoter activity in Huh7 cells (right). **b** Promoter activity in HBV (+) and HBV (−) cells (left). Then, the promoter activity in Huh7 cells was examined after HBV or HBx overexpression (right). **c** The effect of EGR1 on promoter activity (left). The EGR1 binding site in the miR-3928v promoter was mutated, and the luciferase activity induced by EGR1 was examined (right). **d** ChIP analysis (left) and EMSAs (right) revealed that EGR1 directly binds to the miR-3928v promoter. **e** The miR-3928v expression level was measured by RT-qPCR after EGR1 overexpression or knockdown. **f** Blocking EGR1 inhibited HBx-induced miR-3928v promoter activity. **g** Representative IHC images showing the magnitude of EGR1 expression in tissues isolated from liver cancer patients. **h** Total and nuclear expression of EGR1 and P65 in Huh7 cells after transfection with HBx was analyzed by Western blot. **i** An immunofluorescence assay was used to detect the induction of EGR1 expression in the nucleus by HBx in Huh7 cells. **j** Mechanism by which HBx-induced miR-3928v expression contributes to HCC malignancy. (\*: *P* \< 0.05, \*\*: *P* \< 0.01)

Qiaoge Zhang, Ge Song and Hua Tang contributed equally to this work.
